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BACKGROUND: Asthma often complicates pregnancy and represents a risk of serious pregnancy
complications. The complement system contributes to asthma pathogenesis and is up-regulated in
healthy gestation as well. The anaphylatoxin C5a has a major pro-inflammatory role, and the
complement factor H is a main soluble regulator protein both in asthma and during pregnancy;
however, peripheral levels of these complement factors and their relationship to disease control
have not yet been evaluated in pregnant subjects with asthma. METHODS: The present study
aimed to investigate circulating C5a and complement factor H levels in asthma (non-pregnant
subjects with asthma; n  19) and in pregnancy with asthma (pregnant subjects with asthma;
n  22), compared with healthy non-pregnant (n  21) and healthy pregnant women (n  13) and
to test their relationship to clinical parameters of asthma (lung function, airway inflammation, and
symptoms). RESULTS: Circulating C5a levels were higher in the pregnant asthma subject group
compared with the healthy non-pregnant, healthy pregnant, and non-pregnant asthma groups:
median 2.629 (interquartile range [IQR] 2.257–3.052) ng/mL versus 1.84 (IQR 1.576–2.563), 1.783
(IQR 0.6064–2.786), and 2.024 (IQR 1.232–2.615) ng/mL, respectively (P  .02 in all cases). C5a
correlated negatively with FEV1 (r  0.44, P  .039) and FVC values (r  0.64, P  .001) in
the pregnant asthma group and positively with fraction of exhaled nitric oxide levels in the non-
pregnant asthma group (n  12, r  0.78, P  .004). Complement factor H levels were elevated in
both the healthy pregnant and pregnant asthma subject groups compared with the healthy non-preg-
nant group (median 1,082 [IQR 734.9–1,224] and 910.7 [IQR 614.5–1076] g/mL vs 559.7 [IQR 388.7–
783.1] g/mL, P  .002 and P  .004, respectively) but not in the pregnant asthma group compared with
the non-pregnant asthma group (median 687.4 [IQR 441.6–947.6] g/mL, P  .10). CONCLUSIONS:
Asthma during pregnancy increases the circulating level of pro-inflammatory C5a, which is accompa-
nied by impaired lung function and partly counteracted by the gestation-specific elevation of regulatory
complement factor H level (detected in pregnancy both in healthy and subjects with asthma). Key words:
asthma; pregnancy; complement; C5a; complement factor H; biomarker. [Respir Care 2016;61(4):502–509.
© 2016 Daedalus Enterprises]
Introduction
Asthma is a chronic inflammatory disease of the air-
ways characterized by variable and recurring symptoms,
heightened local inflammation, and reversible air flow ob-
struction. It imposes a high burden of morbidity, espe-
cially if not controlled, which occurs in up to 50% of cases
worldwide.1 At the same time, asthma is one of the most
common chronic diseases complicating pregnancy, occur-
ring in 8–12% of all gestations.2 It represents a risk of
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potentially serious maternal and fetal morbidities, in-
cluding preterm delivery, gestational hypertension, pre-
eclampsia, low birthweight, and neonatal mortality.3,4
In addition, pregnancy may also influence asthma con-
trol with the deterioration of symptoms in one third of
all pregnant women with asthma.5 Notably, if the dis-
ease is well controlled, the risks of poor pregnancy
outcomes decrease6; therefore, maintaining optimal con-
trol in this period is crucial. Hence, it would be espe-
cially important to understand the immune interactions
between asthma and gestation and to have a more de-
tailed view into inflammatory processes of asthma dur-
ing pregnancy. Furthermore, because pregnancy itself
can influence spirometry results,7 and because most of
the available techniques used to determine asthma air-
way inflammation (eg, induced sputum) are semi-inva-
sive and therefore cannot be used in pregnancy, circu-
lating, non-invasively obtainable biomarkers related to
asthma control could help in identifying pregnant women
with asthma with elevated risk. However, to date, ob-
jective circulating markers reflecting asthma control are
not known. Previously, we investigated 2 promising
blood markers, but both of them proved to be helpful in
asthma alone rather than in asthma during pregnancy.8,9
The complement system is an ancient danger-sensing
component of innate immunity. Its functions include
recognizing and eliminating microorganisms, immune
complexes, and apoptotic cells, and it has a regulatory
role influencing both innate and adaptive immunity.10 It
can be activated through the so-called classical, alter-
native, and lectin pathways. The complement system
participates in the pathogenesis of asthma on several
levels.11,12 An interesting element of this complex sys-
tem is the fragment C5a, because it has a dual role in
allergic inflammation. On one hand, it protects against
Th2-mediated airway inflammation in the initial phase
of sensitization by modulating dendritic cells, but on the
other hand, it enhances airway inflammation and hyper-
reactivity in already established disease.11,12 In the lat-
ter case, it behaves as a major pro-inflammatory medi-
ator by promoting chemotaxis and activation of many
cell types, which results in release of cytokines, increased
vascular permeability, and smooth muscle contraction. Ele-
vated C5a levels were measured not only in bronchoalveolar
lavage fluid13 and induced sputum of subjects with asthma,14
but also in their plasma15; moreover, plasma levels correlated
with asthma severity.15
Complement factor H is one of the soluble inhibitor
molecules that regulate complement activation, and it is
a major alternative pathway regulator. Imbalances in
complement factor H and its regulatory role contribute
to tissue injury and can result in autoimmune diseases.16
In our earlier study,17 we found increased sputum (but
not circulating) complement factor H concentration in
subjects with asthma, which correlated with asthma con-
trol but not with plasma complement factor H.
Normal human pregnancy is characterized by an up-
regulated complement system but at the same time by
an immune tolerance. Thus, excess complement activa-
tion leads to pregnancy complications. Both C5a18 and
complement factor H19 levels were found to be higher in
healthy pregnancy than in non-pregnant controls, but
plasma C5a levels were further elevated in spontaneous
abortion20 and preeclampsia.21,22 However, to date, data
on circulating C5a and complement factor H levels
and their possible relationship to disease control are
scarce in asthma and lacking for pregnant women with
asthma.
Therefore, the present study aimed to investigate cir-
culating C5a and complement factor H levels in non-
pregnant and pregnant subjects with asthma. Further-
more, to determine the utility of C5a and complement
factor H as a help in the evaluation of asthma control in
pregnant subjects with asthma, we also investigated their
relationship to major asthma control determinants (lung
function parameters, airway inflammation, and symp-
toms).
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Asthma management during pregnancy can be difficult,
and asthma that is not well controlled represents a risk
of potentially serious maternal and fetal morbidities.
The complement system participates in the pathogene-
sis of asthma and is involved in healthy pregnancy as
well, but excess activation leads to pregnancy compli-
cations.
What this paper contributes to our knowledge
Plasma C5a levels were increased in pregnant women
with asthma, and higher levels implied worse lung
function. Plasma C5a levels were also associated with
airway inflammation in non-pregnant subjects with
asthma. A pregnancy-specific elevation of plasma
complement factor H levels were observed in preg-
nant subjects regardless of concomitant asthma.
C5A AND COMPLEMENT FACTOR H WITH ASTHMA CONTROL IN PREGNANCY
RESPIRATORY CARE • APRIL 2016 VOL 61 NO 4 503
Methods
Ethics Statement
Written informed consent was obtained from the sub-
jects, and our study was reviewed and approved by an
independent ethics committee of the institution (Institu-
tional and Regional Research Ethics Committee of Sem-
melweis Medical University). The study adhered to the
tenets of the most recent revision of the Declaration of
Helsinki.
Study Participants
The study had a cross-sectional design. Nineteen non-
pregnant subjects with asthma, 22 pregnant subjects with
asthma, 21 healthy non-pregnant subjects, and 13 healthy
pregnant subjects were enrolled. Subjects with asthma were
assessed at their regular visit at the out-patient clinic of the
Department of Pulmonology, Semmelweis University.
They had persistent disease, and asthma had been diag-
nosed according to the current guidelines1 at least 6 months
before enrollment. Exclusion criteria were current smok-
ing or 5 pack-years of smoking history, any other chronic
disease (except for allergic rhinitis), acute infection within
4 weeks of measurement, fetal infection, and multi-fetal
gestation. There were no complications in the 2 pregnant
groups. Subjects were asked not to use their medication
12 h before visits. Healthy pregnant subjects were recruited
when attending their scheduled visit at the first Depart-
ment of Obstetrics and Gynecology, Semmelweis Univer-
sity. Healthy non-pregnant controls were volunteers and
had a negative history and negative asthma status upon
detailed physical and routine laboratory examination.
Measurement of Serum C5a and Complement
Factor H Levels
Venous blood samples were collected in EDTA tubes
and were processed within 2 h. Plasma was separated and
stored at 80°C until analyses. The plasma levels of C5a
(Quidel, San Diego, CA) and complement factor H (Hy-
cult, Uden, Netherlands) were determined with ELISA kits
in the same samples.
Lung Function, Fraction of Exhaled Nitric Oxide
Measurements, and Asthma Control Evaluation
Lung function was measured by means of an electronic
spirometer (PDD-301/s, Piston, Budapest, Hungary) ac-
cording to the American Thoracic Society guidelines.23
Three technically acceptable maneuvers were performed,
and the best was used. FEV1, forced FVC, peak expiratory
flow, and airway resistance were recorded in subjects with
asthma (non-pregnant subjects with asthma, n  17; preg-
nant subjects with asthma, n  20).
Airway inflammation was assessed with the fraction of
exhaled nitric oxide (FENO), which was measured with a
NIOX MINO airway inflammation monitor (Aerocrine AB,
Solna, Sweden) according to the European Respiratory
Society/American Thoracic Society recommendations24 in
12 non-pregnant subjects with asthma and 18 pregnant
subjects with asthma.
Asthma control was assessed using the Asthma Control
Test (non-pregnant subjects with asthma, n  16; pregnant
subjects with asthma, n  20) recommended by the cur-
rent asthma guideline.1
Statistics
Data distribution was analyzed by the D’Agostino-Pear-
son normality test. Comparisons between the study groups
were made with the Mann-Whitney, Kruskal-Wallis, and
Dunn post hoc multiple comparison tests. Correlation anal-
yses were performed using the Spearman test due to non-
normal distribution of data. Area under the curve values of
receiver operating characteristic curves were calculated
using standard methods, and data are presented as area
under the curve receiver operating characteristics
(95% CI). P values of .05 were considered significant.
The tests used were 2-tailed. Statistics were calculated
using GraphPad Prism 5 (GraphPad Software, La Jolla,




Clinical data and inflammatory parameters of the 4 study
groups are summarized in Table 1. The median age of
participants in the 4 groups was comparable. Gestational
age at blood sampling and at delivery or fetal birthweight
did not differ between the pregnant subjects with asthma
and healthy pregnant subject groups. The median (IQR)
gestational age was 26.5 (17.75–33.25) and 24 (20.25–25)
weeks in the pregnant subjects with asthma and healthy
pregnant subject group, respectively. Every healthy preg-
nant woman was in the second trimester, whereas 41% of
the pregnant women with asthma were in the third trimes-
ter. None of the subjects who were pregnant showed any
obstetric complications. No difference was detected in the
severity or control of asthma or in the FENO levels between
the non-pregnant and pregnant asthma groups (Table 1).
Daily dose of inhaled corticosteroids (ICS) showed a
trend to be higher in the non-pregnant asthma subject
group than in the pregnant asthma subject group (me-
dian 400 [IQR 400 – 800] g vs 300 [IQR 0 –500] g of
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beclomethasone equivalent, respectively, P  .067; Ta-
ble 1). Fifteen non-pregnant and 12 pregnant subjects
with asthma received ICS treatment. The median (IQR)
Asthma Control Test total scores of 20 (15.5–24) in the
non-pregnant asthma subject group and 20.5 (13–23.5)
in the pregnant asthma subject group showed similar
levels of disease control.
Comparison of Circulating C5a and Complement
Factor H Levels Among the 4 Groups
Asthma itself did not influence peripheral C5a and com-
plement factor H levels, because they were similar in the
healthy non-pregnant subject and non-pregnant asthma sub-
ject groups (median 1.84 [IQR 1.576–2.563] ng/mL vs
2.024 [IQR 1.232–2.615] ng/mL C5a, respectively, P  .98,
and 559.7 [IQR 388.7–783.1] g/mL vs 687.4 [IQR 441.6–
947.6] g/mL complement factor H, respectively, P  .30;
Fig. 1, A and B). Median (IQR) C5a levels were markedly
higher in the pregnant asthma subject group (2.629 [2.257–
3.052] ng/mL) compared with the healthy non-pregnant
subject (1.84 [1.576–2.563] ng/mL, P  .02), healthy preg-
nant subject (1.783 [0.6064–2.786] ng/mL, P  .02), and
non-pregnant asthma subject groups (2.024 [1.232–2.615]
ng/mL, P  .02; Fig. 1A). On the other hand, both healthy
pregnancy and pregnancy in subjects with asthma were
associated with elevation in complement factor H levels
compared with the healthy non-pregnant subject group
(1,082 [IQR 734.9–1,224] and 910.7 [IQR 614.5–1,076]
g/mL vs 559.7 [IQR 388.7–783.1] g/mL, P  .002 and
P  .004, respectively), whereas complement factor H
levels were elevated only in the healthy pregnant group
(P  .03) and not in the pregnant asthma subject group
(P  .10) when compared with the non-pregnant asthma
subject group (687.4 [IQR 441.6–947.6] g/mL; Fig. 1B).
The complement factor H levels did not differ between the
healthy pregnant subject and pregnant asthma subject
groups (P  .29; Fig. 1B). The 2 complement factors
correlated with each other only in the healthy non-preg-
nant subject group (r  0.5, P  .02).
Relationship of C5a and Complement Factor H to
Asthma Control Determinants
Pointing to the possible relationship between comple-
ment activation and airway inflammation, there was a sig-
Table 1. Clinical Data in the 4 Study Groups
Parameters
HNP (n  21),
Median (IQR)
HP (n  13) ANP (n  19) AP (n  22)
Median (IQR) n Median (IQR) n Median (IQR) n
Age, y 29 (26.25–33.25) 33 (28.5–36) 35 (26–37) 31.5 (26.5–35)
Gestational age at sampling, wks 24 (20.25–25) 26.5 (17.75–33.25)
2nd/3rd trimester, n 13/0 13/9
Gestational age at delivery, wks 39 (39–40) 11 40 (38–41) 16
Fetal birth weight, g 3,600 (3,228–3,715) 12 3,415 (3,029–4,030) 20
FEV1, L 3.01 (2.57–3.37) 17 2.87 (2.76–3.18) 20
FEV1, % predicted 98 (85–107) 17 92 (85–99.25) 20
FVC, L 3.94 (3.43–4.205) 17 3.82 (3.3–4.165) 20
FVC, % predicted 108 (96.5–116) 17 102.5 (96.25–111.5
PEF, L/s 5.92 (5.25–7.185) 17 6.31 (5.56–6.815) 20
PEF, % predicted 81 (74.5–101.5) 17 84 (76.75–93) 20
Raw, % predicted 123 (105.5–154) 17 115 (82–136) 20
ACT total score 20 (15.5–24) 16 20.5 (13–23.5) 20
FENO, ppb 19 (10.5–22) 12 19 (14.25–39) 18
Daily dose of ICS, g of
beclomethasone equivalent




HNP  healthy non-pregnant
HP  healthy pregnant
ANP  asthma, non-pregnant
AP  asthma, pregnant
IQR  interquartile range
PEF  peak expiratory flow
Raw  airway resistance
ACT  Asthma Control Test
FENO  fraction of exhaled nitric oxide
ICS  inhaled corticosteroid
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nificant positive correlation between C5a and FENO levels
(n  12, r  0.78, P  .004; Fig. 2) in the non-pregnant
asthma subject group. Furthermore, in the pregnant asthma
subject group, C5a levels correlated negatively with FEV1
(r  0.44, P  .039; Fig. 3A) and FVC values (r  0.64,
P  .001; Fig. 3B).
To obtain a more detailed view on the interactions of
asthma air flow obstruction and inflammation, the rela-
tionship of complement factor H levels with lung func-
tion was also examined. However, a trend toward a
correlation between complement factor H levels and
peak expiratory flow values (n  11; r  0.61, P  .052)
could be observed only in the subgroup of pregnant
subjects with asthma in the second trimester and not in
the whole pregnant asthma subject cohort (P  .05). We
did not find further correlations between the comple-
ment factors and any of the remaining lung function
parameters or Asthma Control Test total scores.
Age of the participants did not influence the level of the
2 complement factors in any of the groups. The prescribed
dose of the ICS was not related to either complement level.
ROC Analysis of C5a and Complement Factor H
Levels in Controlled and Uncontrolled Asthma
In order to evaluate the possible utility of C5a and com-
plement factor H measurements in the detection of uncon-
trolled asthma, ROC analyses of C5a and complement
factor H levels were performed in subgroups of pregnant
and non-pregnant subjects with asthma with peak expira-
tory flow above and below 80% and Asthma Control Test
total score above and below 20, because the current GINA
guideline suggests these cut-off values to differentiate be-
tween optimal and suboptimal asthma control.1 We did not
find any significant effect of the 2 proteins in the detection
of suboptimal asthma control.
Relationship of Complement Factors and Functional
Parameters to Obstetric Data
C5a and complement factor H concentrations were not
related to gestational age at sampling in the pregnant asthma
subject nor in the healthy pregnant subject group. There
was no difference between C5a or complement factor H
values of pregnant women with asthma in the second ver-
sus the third trimester.
We could not detect any association between C5a or
complement factor H levels and obstetric data, such as
gestational age at delivery and fetal birthweight. In the
healthy pregnant group, women carrying female fetuses
had slightly higher complement factor H levels compared
Fig. 1. Median (interquartile range) circulating C5a (A) and complement factor H (CFH) (B) levels measured in non-pregnant and pregnant
healthy subjects and in non-pregnant and pregnant subjects with asthma; C5a, 1.84 (1.576–2.563), 1.783 (0.6064–2.786), 2.024 (1.232–
2.615), and 2.629 (2.257–3.052) ng/mL, respectively; complement factor H, 559.7 (388.7–783.1), 1,082 (734.9–1,224), 687.4 (441.6–947.6),
and 910.7 (614.5–1,076) g/mL, respectively. * P  .05 versus healthy  non-pregnant subjects. † P  .05 versus healthy pregnant
subjects. ‡ P  .05 versus asthma  non-pregnant subjects.
Fig. 2. Positive correlation between circulating C5a and fraction of
exhaled nitric oxide (FENO) levels in non-pregnant subjects with
asthma (n  12).
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with those carrying male fetuses, a difference that reached
only the level of a trend (P  .07).
Discussion
The complement system plays an important role in the
development of asthma11,12; therefore, evaluation of this
complex system could potentially help to better under-
stand the disease and may even serve as a biomarker pool
for asthma control. This latter possibility is especially im-
portant during pregnancy in order to maintain optimal
asthma control and thus prevent unwanted effects of the
disease on pregnancy outcomes.6 For the first time, in
the present study, we investigated 2 major proteins of the
complement cascade, C5a and complement factor H, in
pregnant subjects with asthma compared with non-preg-
nant subjects with asthma and with healthy pregnant and
non-pregnant subjects. C5a levels were increased solely in
pregnant women with asthma, and higher C5a levels im-
plied worse lung function in these subjects with regard to
both FEV1 and FVC. C5a levels were found to be associ-
ated also with airway inflammation because they corre-
lated with FENO levels in non-pregnant subjects. On the
other hand, a pregnancy-specific elevation of regulatory
complement factor H levels was demonstrated in both preg-
nant groups regardless of concomitant asthma.
The anaphylatoxin C5a, a cleaved fragment of C5, is
one of the highly inflammatory key effector molecules of
the complement system.25 In contrast, complement factor
H is a major soluble regulator primarily of the alternative
and classical pathways.26 Having homeostatic roles, a cer-
tain degree of spontaneous activation of the complement
system can always be found in healthy people, indicating
a controlled working of this ancient danger-sensing system
in normal conditions; however, a delicate balance of acti-
vation and regulation is important to preclude normal self-
tissue damage.10,27 We found a correlation between C5a
and complement factor H in the healthy control popula-
tion, presumably suggesting a balanced state between ac-
tivation and regulation.
C5a has a dual role in asthma: During the phase of
sensitization, it protects against the initiation of Th2-me-
diated airway inflammation, but in already established dis-
ease, it becomes highly pro-inflammatory and further en-
hances airway hyperreactivity.11,12,28 C5a may contribute
to airway inflammation in asthma,11,12,28 which was re-
flected in the correlation between C5a and FENO levels in
non-pregnant subjects with asthma in our study. Further-
more, inhibition of C5a improved lung function, airway
hyperreactivity, and airway inflammation in animal mod-
els and in mild allergic asthma subjects.29,30 FENO levels
were not evaluated in the healthy pregnant group, since,
according to our previous data, pregnancy itself does not
have an influence on normal FENO values.31
As a novel finding of our study, we demonstrated an
asthma-induced increase in circulating C5a levels in preg-
nant subjects with asthma, which was not detected either
in healthy pregnant women or in any other group and
which was associated with impaired lung function with
regard to both FEV1 and FVC in pregnant subjects with
asthma. A limitation of our study was that lung function
was not measured in healthy control groups, and therefore
our results confirm a negative correlation between C5a
levels and FEV1 and FVC values only in the pregnant
asthma subject group; no conclusion can be drawn regard-
ing this issue in healthy pregnancy. Higher concentrations
of complement anaphylatoxins (eg, C5a) may cause recur-
rent spontaneous abortion,20,32 preterm birth,33,34 and pre-
eclampsia,21,22 whereas treatment with the C5 inhibitor
eculizumab may have therapeutic relevance in these con-
ditions.35 Importantly, eculizumab seems to be adminis-
trable safely in pregnancy in the long term.36,37 In our
study, we found similar C5a levels in healthy pregnant and
non-pregnant women and could not detect any association
between C5a levels and obstetric parameters, such as fetal
birthweight or gestational week at delivery; of note, these
pregnancies were without complications.
Elevation of complement factor H in healthy pregnancy
was already known earlier,19 and we confirmed this again,
but here we also tested whether this pregnancy-specific
Fig. 3. Negative correlation between circulating C5a levels and FEV1 (A) and FVC (B) values in pregnant women with asthma (n  20).
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elevation is present in pregnant women with asthma as
well. Indeed, asthma did not suppress the elevation of
complement factor H in our pregnant subjects compared
with healthy ones, so that complement factor H was ele-
vated in both pregnant groups regardless of the presence of
asthma; however, it must be noted that the majority of
pregnant women with asthma were ICS-treated and well-
controlled. In addition, hormonal and physiological changes
of pregnancy may differ across trimesters, which might
influence our results. Nevertheless, if regulators (such as
complement factor H) are dysfunctional during pregnancy,
excessive complement activation may lead to placental
damage and preeclampsia.38–40 In our study, none of the
women showed any obstetric complications in any preg-
nant group, which may be, at least partly, a result of well
balanced complement activation.
In our previous study, only induced sputum levels of
complement factor H were increased in asthma and were
related to worse lung function, whereas plasma levels were
not elevated and did not correlate with any clinical param-
eter.17 This latter finding was supported by the current
study, because in non-pregnant subjects, we could not dem-
onstrate any association between plasma complement fac-
tor H levels and asthma control determinants. However, in
the subgroup of second-trimester pregnant women with
asthma, complement factor H levels showed a trend to-
ward a direct correlation with peak expiratory flow. This
phenomenon might imply that more rigorous control of
complement activation could be beneficial during the preg-
nancy of asthma patients; notably, a significantly large
sample size evaluation would be warranted to confirm our
observation. A possible reason why pregnant subjects re-
ceived a somewhat lower dose of ICS is that pregnant
women are less adherent in taking the prescribed ICS reg-
ularly.2,5 This may theoretically also explain why the
association between complement factor H and peak ex-
piratory flow was detectable only in pregnant and not in
non-pregnant subjects. However, because ICS dose did
not influence plasma complement factor H levels sig-
nificantly in any of the groups, this explanation remains
hypothetical.
Conclusions
According to our data, the circulating level of pro-in-
flammatory C5a is elevated in pregnant women with asthma
and shows a relationship to impaired lung function in this
patient group. On the other hand, pregnancies of both
healthy and subjects with asthma increase the level of
regulatory complement factor H, which seems to be a
pregnancy-specific change independent of concomitant
asthma.
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